MedTrace Logo

Measurement of Blood Volume Loss During Burn Surgery

NCT03340116 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-10-15

No results posted yet for this study

Summary

Burn surgery is associated with significant reductions in hematocrit. However, it is unclear whether these reductions are the result of hemodilution from non-red cell containing intraoperative transfusions or from loss of red blood cells. The investigators will be using the Daxor Blood Volume Analyzer (BVA-100), an FDA approved instrument that can measure total blood volume, plasma volume, and RBC volume using the indicator dilution technique. By comparing pre-operative measurements of blood volume, plasma volume, and RBC volume to that of post-operative measurements after burn surgery, the investigators can determine the primary cause of the reduction in hematocrit associated with burn surgery. The investigators hypothesize that these reductions in hematocrit are primarily the result of hemodilution rather than blood loss and that there will be a statistically significant difference in measured plasma volume from the pre-operative group to the post-operative group.

Conditions

  • Surgical Blood Loss
  • Burns

Interventions

PROCEDURE

Burn surgery

Burn surgery including wound debridement, skin grafting

DIAGNOSTIC_TEST

Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100

Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100

Sponsors & Collaborators

  • Daxor Corporation

    collaborator INDUSTRY

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Mark Nelson, MD · VCU Medical Center

  • Michael Feldman, MD · VCU Medical Center

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2021-01-31
Completion
2021-01-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03340116 on ClinicalTrials.gov